CLVS
Income statement / Annual
Last year (2021), Clovis Oncology, Inc.'s total revenue was $148.76 M,
a decrease of 9.58% from the previous year.
In 2021, Clovis Oncology, Inc.'s net income was -$264.52 M.
See Clovis Oncology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$148.76 M |
$164.52 M |
$143.01 M |
$95.39 M |
$55.51 M |
$78,000.00 |
$0.00 |
$13.63 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$38.83 M
|
$41.31 M
|
$34.69 M
|
$22.07 M
|
$11.74 M
|
$70,000.00
|
$376.72 M
|
$158.46 M
|
$83.77 M
|
$73.78 M
|
| Gross Profit |
$109.93 M
|
$123.22 M
|
$108.32 M
|
$73.31 M
|
$43.77 M
|
$8,000.00
|
-$376.72 M
|
-$144.83 M
|
-$83.77 M
|
-$73.78 M
|
| Gross Profit Ratio |
0.74
|
0.75
|
0.76
|
0.77
|
0.79
|
0.1
|
0
|
-10.63
|
0
|
0
|
| Research and Development Expenses |
$192.08 M
|
$257.71 M
|
$283.15 M
|
$231.35 M
|
$142.50 M
|
$251.13 M
|
$269.25 M
|
$137.71 M
|
$66.55 M
|
$58.89 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$182.77 M
|
$175.78 M
|
$138.91 M
|
$40.73 M
|
$30.52 M
|
$21.46 M
|
$16.57 M
|
$10.64 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$128.40 M
|
$163.89 M
|
$182.77 M
|
$175.78 M
|
$138.91 M
|
$40.73 M
|
$30.52 M
|
$21.46 M
|
$16.57 M
|
$10.64 M
|
| Other Expenses |
$15.22 M
|
$167.70 M
|
$9.71 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$335.70 M
|
$425.41 M
|
$475.63 M
|
$407.13 M
|
$281.41 M
|
$291.86 M
|
$299.78 M
|
$159.16 M
|
$83.11 M
|
$69.53 M
|
| Cost And Expenses |
$374.52 M
|
$466.71 M
|
$510.31 M
|
$429.20 M
|
$293.14 M
|
$291.93 M
|
$299.78 M
|
$159.16 M
|
$83.11 M
|
$69.53 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$31.67 M
|
$23.49 M
|
$16.55 M
|
$13.18 M
|
$10.43 M
|
$8.49 M
|
$8.37 M
|
$2.60 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$8.50 M
|
$8.20 M
|
$7.77 M
|
$4.60 M
|
$2.50 M
|
$1.14 M
|
$761,000.00
|
$4.22 M
|
$250,000.00
|
$353,000.00
|
| EBITDA |
-$114.35 M |
-$338.07 M |
-$798.26 M |
-$333.81 M |
-$237.63 M |
-$291.85 M |
-$676.50 M |
-$317.62 M |
-$166.88 M |
-$143.31 M |
| EBITDA Ratio |
-1.51
|
-2.05
|
-2.62
|
-3.67
|
-6.07
|
-4763.32
|
0
|
-11.08
|
0
|
0
|
| Operating Income Ratio |
-1.57
|
-1.84
|
-2.63
|
-3.5
|
-4.28
|
-4778.63
|
0
|
-11.63
|
0
|
0
|
| Total Other Income/Expenses Net |
-$31.67 M
|
$308.92 M
|
-$21.88 M
|
-$33.59 M
|
-$112.34 M
|
-$8.44 M
|
-$5.22 M
|
$159.90 M
|
$82.40 M
|
$69.30 M
|
| Income Before Tax |
-$264.93 M
|
-$369.76 M
|
-$398.63 M
|
-$367.40 M
|
-$349.98 M
|
-$381.17 M
|
-$381.94 M
|
-$157.72 M
|
-$84.48 M
|
-$74.01 M
|
| Income Before Tax Ratio |
-1.78
|
-2.25
|
-2.79
|
-3.85
|
-6.3
|
-4886.81
|
0
|
-11.58
|
0
|
0
|
| Income Tax Expense |
-$404,000.00
|
-$547,000.00
|
$1.80 M
|
$608,000.00
|
-$3.58 M
|
-$32.03 M
|
-$29.08 M
|
$2.31 M
|
$52,000.00
|
-$27,000.00
|
| Net Income |
-$264.52 M
|
-$369.21 M
|
-$400.42 M
|
-$368.01 M
|
-$346.40 M
|
-$349.14 M
|
-$352.86 M
|
-$160.03 M
|
-$84.53 M
|
-$73.98 M
|
| Net Income Ratio |
-1.78
|
-2.24
|
-2.8
|
-3.86
|
-6.24
|
-4476.12
|
0
|
-11.75
|
0
|
0
|
| EPS |
-2.18 |
-4.38 |
-7.43 |
-7.07 |
-7.36 |
-9.07 |
-9.79 |
-4.72 |
-2.95 |
-2.97 |
| EPS Diluted |
-2.18 |
-4.38 |
-7.43 |
-7.07 |
-7.36 |
-9.07 |
-9.79 |
-4.72 |
-2.95 |
-2.97 |
| Weighted Average Shares Out |
$121.22 M
|
$84.31 M
|
$53.87 M
|
$52.07 M
|
$47.05 M
|
$38.48 M
|
$36.03 M
|
$33.89 M
|
$28.67 M
|
$24.92 M
|
| Weighted Average Shares Out Diluted |
$121.22 M
|
$84.31 M
|
$53.87 M
|
$52.07 M
|
$47.05 M
|
$38.48 M
|
$36.03 M
|
$33.89 M
|
$28.67 M
|
$24.92 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
